Back to today’s briefing

Story perspectives

Vivani's Year-Long Semaglutide Implant Shows 20% Rat Weight Loss

7/11/2026

44 3 Full Breakdown

Summary

Story summary

Vivani Medical announced a semaglutide implant for the United States to improve GLP-1 adherence.
The titanium device releases the drug through a membrane with microscopic channels for up to a year and can be implanted in minutes under local anesthesia.
Pre-clinical rat data showed roughly 20% weight loss over six months.
Novo Nordisk will evaluate the NPM-139 implant while doctors warn that training and insurance challenges could impede adoption.

1 of 1

Story summary

Vivani Medical announced a semaglutide implant for the United States to improve GLP-1 adherence.
The titanium device releases the drug through a membrane with microscopic channels for up to a year and can be implanted in minutes under local anesthesia.
Pre-clinical rat data showed roughly 20% weight loss over six months.
Novo Nordisk will evaluate the NPM-139 implant while doctors warn that training and insurance challenges could impede adoption.